These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33636042)

  • 1. Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism.
    Röshammar D; Huang F; Albisetti M; Bomgaars L; Chalmers E; Luciani M; Halton J; Mitchell LG; Bergstrand M; Ibrahim MMA; Joseph D; Tartakovsky I; Gropper S; Brueckmann M; Brandão LR
    J Thromb Haemost; 2021 May; 19(5):1259-1270. PubMed ID: 33636042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability.
    Halton JML; Albisetti M; Biss B; Bomgaars L; Brueckmann M; Gropper S; Harper R; Huang F; Luciani M; Maas H; Tartakovsky I; Mitchell LG
    J Thromb Haemost; 2017 Nov; 15(11):2147-2157. PubMed ID: 28921890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.
    Halton JML; Picard AC; Harper R; Huang F; Brueckmann M; Gropper S; Maas H; Tartakovsky I; Nurmeev I; Mitchell LG; Brandão LR; Chalmers E; Albisetti M
    Thromb Haemost; 2017 Nov; 117(11):2168-2175. PubMed ID: 29202215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa study.
    Halton JM; Lehr T; Cronin L; Lobmeyer MT; Haertter S; Belletrutti M; Mitchell LG
    Thromb Haemost; 2016 Aug; 116(3):461-71. PubMed ID: 27357738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.
    Halton J; Brandão LR; Luciani M; Bomgaars L; Chalmers E; Mitchell LG; Nurmeev I; Sharathkumar A; Svirin P; Gorbatikov K; Tartakovsky I; Simetzberger M; Huang F; Sun Z; Kreuzer J; Gropper S; Reilly P; Brueckmann M; Albisetti M;
    Lancet Haematol; 2021 Jan; 8(1):e22-e33. PubMed ID: 33290737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial.
    Liesenfeld KH; Lehr T; Dansirikul C; Reilly PA; Connolly SJ; Ezekowitz MD; Yusuf S; Wallentin L; Haertter S; Staab A
    J Thromb Haemost; 2011 Nov; 9(11):2168-75. PubMed ID: 21972820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials.
    Mitchell LG; Röshammar D; Huang F; Albisetti M; Brandão LR; Bomgaars L; Chalmers E; Halton J; Luciani M; Joseph D; Tartakovsky I; Gropper S; Brueckmann M
    Thromb Haemost; 2022 Sep; 122(9):1573-1583. PubMed ID: 35909257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism.
    Paik J
    Paediatr Drugs; 2022 Jul; 24(4):423-431. PubMed ID: 35699915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and rationale for the DIVERSITY study: An open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism.
    Albisetti M; Biss B; Bomgaars L; Brandão LR; Brueckmann M; Chalmers E; Gropper S; Harper R; Huang F; Luciani M; Manastirski I; Mitchell LG; Tartakovsky I; Wang B; Halton JML
    Res Pract Thromb Haemost; 2018 Apr; 2(2):347-356. PubMed ID: 30046738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.
    Brandão LR; Albisetti M; Halton J; Bomgaars L; Chalmers E; Mitchell LG; Nurmeev I; Svirin P; Kuhn T; Zapletal O; Tartakovsky I; Simetzberger M; Huang F; Sun Z; Kreuzer J; Gropper S; Brueckmann M; Luciani M;
    Blood; 2020 Feb; 135(7):491-504. PubMed ID: 31805182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
    Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
    Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
    Fanola CL
    Vasc Health Risk Manag; 2015; 11():271-82. PubMed ID: 26064057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence.
    Greig SL; McKeage K
    Drugs; 2014 Oct; 74(15):1785-800. PubMed ID: 25270377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
    Eriksson BI; Dahl OE; Ahnfelt L; Kälebo P; Stangier J; Nehmiz G; Hermansson K; Kohlbrenner V
    J Thromb Haemost; 2004 Sep; 2(9):1573-80. PubMed ID: 15333033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran for the treatment of venous thromboembolism.
    Schellong SM
    Expert Rev Hematol; 2015 Aug; 8(4):413-25. PubMed ID: 26111881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling and Simulation Analysis of Aprepitant Pharmacokinetics in Pediatric Patients With Postoperative or Chemotherapy-Induced Nausea and Vomiting.
    Chain A; Wrishko R; Vasilinin G; Mouksassi S
    J Pediatr Pharmacol Ther; 2020; 25(6):528-539. PubMed ID: 32839657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism.
    Damle B; Jen F; Sherman N; Jani D; Sweeney K
    J Clin Pharmacol; 2021 Feb; 61(2):172-180. PubMed ID: 32827160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design.
    Luciani M; Albisetti M; Biss B; Bomgaars L; Brueckmann M; Chalmers E; Gropper S; Halton JML; Harper R; Huang F; Manastirski I; Mitchell LG; Tartakovsky I; Wang B; Brandão LR
    Res Pract Thromb Haemost; 2018 Jul; 2(3):580-590. PubMed ID: 30046763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™.
    Goldhaber SZ; Eriksson H; Kakkar A; Schellong S; Feuring M; Fraessdorf M; Kreuzer J; Schueler E; Schulman S
    Vasc Med; 2016 Dec; 21(6):506-514. PubMed ID: 27807306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
    Reilly PA; Lehr T; Haertter S; Connolly SJ; Yusuf S; Eikelboom JW; Ezekowitz MD; Nehmiz G; Wang S; Wallentin L;
    J Am Coll Cardiol; 2014 Feb; 63(4):321-8. PubMed ID: 24076487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.